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Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic
metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with
a dark prognosis because of underlying liver diseases and an often late diagnosis. A curative surgical treatment can therefore only
be proposed in 20 to 30% of the patients. However, new treatment options for intermediate to advanced stages, such as internal
radionuclide therapy, seem particularly attractive. Transarterial radioembolization (TARE), which consists in the use of intra-
arterial injection of a radiolabelled embolising agent, has led to very promising results. TARE with 90Y-loaded microspheres is
now becoming an established procedure to treat liver tumours, with two commercially available products (namely, SIR-Sphere
andTheraSphere). However, this technology remains expensive and is thus not available everywhere.The aim of this review is to
describe TARE alternative technologies currently developed and investigated in clinical trials, with special emphasis on HCC.
1. Introduction
Primary tumours (with hepatocellular carcinoma accounting
for 75-80% of them) or secondary hepatic metastases are a
major cause of death, with an increasing incidence [1, 2].
Hepatocellular carcinoma (HCC) is the fifth cancer in terms
of incidence and the second leading cause of cancer death
for men worldwide [3]. The vast majority of cases occurs
in Southeast Asia [4], China alone representing half of the
worldwide cases and deaths, and an increasing incidence in
Europe. The presence of a cirrhosis, associated with various
possible etiologies (such as hepatitis viral infections, alcohol,
and haemochromatosis), is the primary risk factor. 73.4%
of HCC can be attributed to hepatitis infections [5, 6], but
the nature of the underlying disease mainly depends on
geographical region or ethnic group. For instance, inAsia, 70-
80% of all HCCs are attributable to hepatitis B virus (HBV)
[4, 7], with the notable exception of Japan, where hepatitis
C (HCV) is the main factor [4]. In the Western world,
the main causes of HCC are alcoholism and nonalcoholic
steatohepatitis (NASH), linked with a dramatic rise in obesity
and diabetes occurrence, with also a strong increase in
chronic hepatitis C [8, 9].
Despite the large range of treatment options developed
over the years [10, 11], HCC prognosis remains dark, with a
5-year survival below 5%.The only really curative treatments
are surgery (resection, transplantation) and ablative tech-
niques (radiofrequency, cryotherapy, percutaneous alcohol
injection). However, because of the underlying liver diseases
(fibrosis, cirrhosis) and an often late diagnosis, a curative
treatment can only be proposed in 20 to 30% of cases.
Indeed, the presence of multiple foci, intraportal or extra-
hepatic metastases, and impaired hepatic functions are con-
traindications for liver transplantation or tumour resection.
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Figure 1: BCLC staging system and therapeutic strategy according to EASL-EORTC guidelines. © European Association for the Study of the
Liver; European Organisation for Research and Treatment of Cancer. (Adapted from J Hepatol 2012; 56: 908-43.)
Additionally, even for such patients, recurrences are still likely
to occur (up to 50% recurrence rate at 2 years for resection
and, for transplantation, 10% within Milan criteria, but as
high as 40% for patients outside Milan criteria) [12]. For
nonoperable tumours, various palliative treatments may be
proposed depending on the tumour staging. A large range
of staging systems have been proposed [9, 13]. Most groups,
especially in Europe, currently use the BCLC (Barcelona
Clinic Liver Cancer), recommended by the EASL-EORTC
(Figure 1). For intermediate stage HCCs, since external
radiotherapy is of little use because of the high risk of
hepatic toxicity, despite recent improvements in its efficacy
and tolerance [14, 15], and systemic chemotherapy has not yet
demonstrated effectiveness, with a low level of response with-
out any improvement in survival [16], patients are generally
proposed locoregional therapies [17]. For advanced HCCs,
targeted treatment with sorafenib, and/or recently authorised
regorafenib or other promising kinase inhibitors remains the
only possibility [18, 19].
Due to both dual blood supply of the liver from the
portal vein and the hepatic artery, and the sinusoidal
cytoarchitecture of the liver parenchyma, the invasion of
circulating tumour cells for establishing secondary hepatic
metastatic foci is greatly favoured. 95% of hepatic malig-
nancies are in fact secondary tumours [2]. So, for instance,
liver metastases occur in approximately 50% of patients with
colorectal carcinoma (CRC) [20], and in 44% of patients with
neuroendocrine tumours (NET) [21]. Depending on volume
and number of the metastases and histology of the original
tumour, the median survival of patients with liver metastases
ranges from 2 to 12 months [22]. To treat these intrahepatic
metastases, surgery is considered the gold standard for CRC
liver metastases [23] while its use remains controversial for
metastases from non-colorectal primary tumours [21]. When
surgery is not possible, because of the number of metastases,
liver-directed therapies help in prolonging survival [17]. In
the case of primary NET liver metastases, peptide-receptor
radionuclide therapy (PRRT)with radiolabelled somatostatin
analogues seems appealing [24–26].
Taking advantage of this dual blood supply and a rich
vasculature, intra-arterially delivered treatments, such as
transarterial chemoembolization (TACE) and transarterial
radioembolization (TARE), appear as really attractive treat-
ment modalities. TACE, consisting in intra-arterial injection
of an emulsion of Lipiodol and a chemotherapeutic drug,
followed by the occlusion of the feeding artery, is currently
considered as the standard of care for intermediate stage
HCCs and somemetastases [27], but its effectiveness remains
a matter of debate. In this context, the development of a well-
tolerated treatment modality appears particularly attractive.
TARE, consisting in the intra-arterial delivery of a radioactive
material to the tumour, limiting systemic irradiation and
preserving the healthy liver to a maximum extent, appears to
be a promising alternative to TACE [28–31]. Different mate-
rials (Lipiodol, glass, resin, or polymer microspheres) and
radioisotopes have been used [32]. Only a few radionuclides
have suitable characteristics for the treatment of tumours,
among them are 32P, 90Y, 131I, 166Ho, 177Lu, and 186/188Re, all
of which are 𝛽-emitters (Table 1). 90Y-loaded microspheres
now have an established role and proved to be safe and
effective in treating primary and secondary liver cancers, with
favourable toxicity profile, with several tens of prospective or
retrospective clinical studies completed or ongoing [15, 33–
35]. There are, however, few Phase III studies, and published
results are up to now disappointing [36, 37], but mostly
because of suboptimal study designs or inadequate patient
selection. Moreover, though this treatment modality has
gained wide acceptance, it remains very expensive, especially
for low-income countries, and is not available everywhere.
Though not as common as TARE with 90Y-microspheres,
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Table 1: Radionuclides used for TARE.
Radionuclide t1/2 (days) E𝛽 (MeV) (%) E𝛾 (keV) (%) Tissue penetration range (mm) Production method
32P 14.3 1.71 (100) / 7.9 Nuclear reactor
90Y 2.7 2.284 (100) / 12
90Sr/90Y generator
Nuclear reactor for microspheres labelling
131I 8 0.81 (90) 0.364 (81) 2 Nuclear reactor
166Ho 1.1 1.84 (50.5) 81 (6.4) 8.7 Nuclear reactor
177Lu 6.7 0.497 (79) 113 (6.4) 2.2 Nuclear ractor
208 (11)
186Re 3.8 1.07 (72) 137 (9) 4.5 Nuclear reactor
188Re 0.7 2.118 (72) 155 (15) 11
188W/188Re generator
Nuclear reactor
Note: t1/2 (days), radioisotope half-life in days; E훽 (MeV) (%), maximum particle energy and respective decay abundance shown in parentheses; E훾 (KeV)
(%), gamma ray energy useful for imaging and respective abundance in total energy emission shown in parentheses; tissue penetration range (mm), maximum
tissue penetration shown in millimeters.
TARE alternative methods are under clinical investigation,
either in primary or in secondary liver cancers and will be
presented here.
2. TARE with Radiolabelled Microspheres
The idea to utilise radiolabelled microspheres to treat
tumours, liver being the first organ successfully treated, dates
back to the 1960s [38]. First isotopes used were phosphorus-
32 (E훽max = 1.71 MeV; t1/2 = 14.3 d, max tissue penetration
= 8 mm) and yttrium-90 (E훽max = 2.28 MeV; t1/2 = 64.0 h,
max tissue penetration = 12 mm), two pure 𝛽-emitters. It
then fell out of use, before being revived in the 1980s until
present day. There are currently two commercially available
90Y-labelled microspheres, based on different technologies
[39].One is based on glassmicrospheres (TheraSphere, BTG
International Ltd., London, United Kingdom); the other is
made of ion-exchange resin (SIR-Sphere, SIRTEX Medical
Limited,North Sidney,NewSouthWales, Australia). Another
TARE device, loaded with holmium-166 (E훽max = 1.84 MeV;
t1/2 = 26.8 h, max tissue penetration = 8.7 mm), has been
recently made available (QuiremSpheres, Quirem Medical
BV, Utrecht, Netherlands) and is currently the subject of clin-
ical trials in liver metastases. Besides these, numerous types
of microspheres with various sizes and labelled with different
isotopes have been developed and studied in humans [40].
2.1. Phosphorus-32 Microspheres. Phosphorus-32 was among
the first isotopes used for therapeutic purposes, thanks to
its suitable properties. In the middle of the 1960s, Caldarola
et al. [41] used 32P-labelled resin microspheres for intra-
arterial treatment of tumours. In 1979,Grady used 32P-CrPO4
colloids to treat intrahepatic metastases in a pilot study [38].
During the time of follow-up (2 years), 3 out of 4 patients
were doing well, without significant side effects. However,
with the rise of 90Y, 32P fell out of use [42], except in China
where 44 patients with unresectable liver cancer were treated
withmoderate results with 32P-glassmicrospheres [43] and in
Iran where 39 patients suffering from primary or secondary
liver cancer were recently treated with intra-arterial injection
of 32P-CrPO4 colloids [44]. This study was, however, based
on imaging parameters and no result on the outcome of the
patients is given.
2.2. Holmium-166 Microspheres. Compared with 90Y, 166Ho
has the advantage of possessing a 𝛾 emission (81 keV)
suitable for SPECT imaging. Moreover, holmium is highly
paramagnetic, thus enabling MRI imaging and quantification
[45, 46]. It has a 26.8 h half-life, resulting in a high dose-
rate, and can be produced pure upon neutron bombardment,
since natural holmium-165 has a 100% abundance and a large
cross section [47]. 166Ho-loaded microspheres have been
prepared using synthetic polymers [48], natural polymers
[49], phosphate [50], resin [51], or glass [52].
2.2.1. Glass Microspheres. Glass is relatively resistant to radi-
ation damage and nontoxic. Glass microspheres can easily be
spheroidized in uniform sizes and can generally be produced
with minimal radionuclidic impurities [53]. Holmium doped
(Ho2O3) aluminium silicate glasses were “melted in an
alumina crucible at 1600∘C in a crucible type electric furnace.
The liquid was held at this temperature for 2 hours and
stirred each 30 min by using a silica rod to assure the liquid
homogenization and gas release”. Brown et al. [54] prepared
166Ho-loaded glass particles with a small size of 2-5 𝜇m for
direct injection into mammary carcinoma tumours in mice,
which led to an effective deposition of intense 𝛽-radiation. It
could therefore be an effective modality for use in localised
internal radionuclide therapy. Yet, no further studies were
reported. In 2009, Costa et al. reported the preparation of
20-50 𝜇m diameter glass particles (considered to be the ideal
particle size to reach the arterioles of the liver), loaded with a
specific activity up to 224 GBq/g of microsphere, suitable for
therapeutic applications [52]. Their reported microspheres
however contained more than 20% of 177Lu, because of the
presence of lutetium oxide in the initial material.
2.2.2. Resin Microspheres. Compared with glass micro-
spheres, ion-exchange resin-based microspheres present with
the advantage of a lower density and commercial availability.
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Schubiger investigated different resins with 90Y and found
that Bio-Rex 70 (Bio-Rad Inc, Hercules CA, USA) was
the most suitable one [55]. Bio-Rex resin is made from
acrylic polymer, with carboxylic groups used to bind the
radiometal. Subramanian et al. recently investigated the
feasibility of using Bio-Rex 70 with 166Ho [56]. 166Ho-labeled
microspheres were obtained in high-yield (94.53% at pH 8.5),
demonstrated high in vivo stability and showed very good
retention in the liver (94.94 ± 1.51% at 72 h pi.). Besides
Bio-Rex resins, Aminex resins (Bio-Rad Inc, Hercules CA,
USA) were also explored. Aminex A-5, based on styrene
divinylbenzene copolymer with sulphonic acid functional
groups, was used [51]. Biodistribution in pigs demonstrated
a reproducible fixation in the liver and dosimetry study,
based on SPECT, allowed determining the required radiation
absorbed dose to the liver to be 25 Gy to reach a therapeutic
activity.
2.2.3. Polymer Microspheres. Polymer-based microspheres
present with the advantage of near-plasma density, biode-
gradability, and biocompatibility [48]. However, this material
is not able to withstand high thermal neutron fluxes [57, 58].
To circumvent this problem,microspheres can be loadedwith
holmium after neutron irradiation, like Suzuki et al. with
chitosan microspheres [59] or Zielhuis et al. with alginate
microspheres [49]. An alternative is to use additives and
to select carefully the irradiation parameters (like avoiding
any traces of water, < 1h irradiation in a high-flux reactor)
[47, 60]. Another important parameter is the stability of
the holmium-166 inside the polymer matrix. Mumper et al.
showed that 𝛽-diketone chelates and particularly acetylaceto-
nate (AcAc) formed strong complexes with holmium and that
itmoreover had a strongmelting point amenable towithstand
the heat inside the reactor without melting [61]. He thus
developed poly-(L-lactic acid) (PLA or sometimes PLLA)
microspheres for the prospective treatment of liver tumours,
prepared by a simple solvent evaporation technique [62].This
method was soon used and furthered by a team fromUtrecht
[60]. Briefly, [165Ho]-AcAc complex and PLA are dissolved
in chloroform, a volatile and water immiscible solvent, and
subsequently added to polyvinyl alcohol aqueous solution.
The resulting solution is emulsified by stirring, thus forming
small organic droplets until the organic solvent evaporates.
As chloroform evaporates, the droplets harden, forming
microspheres, which can be collected through filtration.
Microsphere size can be tuned through speed of stirring. The
resulting microspheres, after drying, are then irradiated into
a nuclear reactor to yield the desired 166Ho-loaded micro-
spheres. Chloroform is a toxic solvent and should be avoided
in patients. It has however been demonstrated that irradia-
tion resulted in the complete removal of chloroform from
the microspheres [63]. Holmium-loaded PLA-microspheres
produced by this method (Figure 2) have been extensively
characterised [47, 58, 64, 65] and are now produced under
Good Manufacturing Practices [66]. Biodistribution studies
demonstrated an effective tumour targeting in rats, with a 6.1
± 2.9 tumour-to-liver ratio at one day after administration
[67]. Animal studies have also established a low toxicity
Figure 2: Scanning-electron microscope image of Holmium-PLA
microspheres (from [73]).
profile in rats followed up to 18 months, with only slight
chronic inflammation, and no release of holmium load, as
assessed with MRI [68]. They also demonstrated that correct
administration of the microspheres was a critical step [69]
and that it was feasible to quantify the dose through MR
imaging [70, 71] and to predict dosimetry with the use of a
scout dose of 166Ho-PLLA-microspheres [72].
Aphase I trial for the treatment of unresectable, chemore-
fractory, liver metastases was consequently initiated [73].
15 patients were treated with escalating aimed whole-liver
absorbed doses of 20, 40, 60, and 80 Gy. At 6weeks, treatment
response was 1 partial response (PR), 7 stabilised disease
(SD), and 7 disease progression (DP). At 12 weeks, treatment
response was 1 PR, 1 SD, and 13 DP.The only PRwas obtained
for a patient treated with 20 Gy to the liver. Results from
this trial showed “166Ho-radioembolization is feasible and
safe for the treatment of patients with liver metastases” and
enables image-guided treatment [74]. Maximum tolerated
dose was determined to be 60 Gy. MRI and SPECT-based
dosimetry were compared and found to be equivalent, with
overall T/N ratios ranging from 0.9 to 2.7 with SPECT
and 1.1 to 3.1 with MRI [75]. Use of a scout dose 166Ho-
microspheres to assess lung shunting and predict dosimetry
was demonstrated to be more accurate than 99mTc-MAA
imaging [76] and proven to be safe, as possible extrahepatic
deposition of the microspheres was estimated to have a low
incidence of 1.3% [77]. Based on these promising results,
a phase II study was launched, with a fixed aimed whole-
liver dose of 60 Gy (or 3.8 GBq/kg of liver tissue, including
the scout dose), in patients with liver metastases refractory
to systemic therapy and ineligible for surgical resection (38
patients were included, one of whom was not evaluable).
Besides 166Ho-scout dose to calculate dosimetry, a scout dose
of 99mTc-MAA was administered to assess the lung shunts
prior to treatment. In the recently published results [78], the
target lesions showed complete response, partial response, or
stabilised disease at 3 months for 27 patients (95% confidence
interval [CI], 57% – 85%). The median overall survival was
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14.5 months (95% CI, 8.6 – 22.8 months). The toxicity profile
was acceptable. Compared to 90Y-microspheres TARE, the
presence of 𝛾-emission does increase radiation exposure to
some extent, but only patients treated with more than 7 GBq
of 166Ho and released within 6 h after treatment (instead of
24 h) would require contact restrictions. In all other cases,
patients can be releasedwithout contact restrictions [79].This
study thus demonstrated clinical efficacy and further studies
should be undergone. Another clinical study is currently
ongoing, comparing a newly developed anti-reflux catheter
to standard microcatheter for radioembolization of patients
with liver-dominant colorectal metastases [80].
In parallel to the development of 166Ho-PLLA-micros-
pheres for liver metastases, 166Ho-chitosan microspheres
were investigated forHCC treatment [59]. Chitosan is a chitin
derivative which can chelate metals and solidifies at alkaline
pH. A phase IIb trial evaluated percutaneous injection of this
device in 40 patients with small HCC [81], while another
phase II trial investigated transarterial injection in 54 patients
with a single large HCC [82]. Both studies reported good
results, with survival rates at 1, 2, and 3 years of 87.2%,
71.8%, and 65.3%, respectively, in the first study and tumour
necrosis achieved in 77.5% of patients with HCC < 3cm and
91.7% of patients with HCC < 2 cm. In the second study,
where tumour size ranged from 3 to 13 cm, response rate
was 78%, with 31 patients having a complete response for
a 27-month median duration. Two treatment-related deaths
were reported. Authors nonetheless found the toxicity to be
acceptable, but patients should be carefully selected. When
categorising patients according to their tumour size, it was
found that patients with tumours of an intermediate size (3–5
cm)were the optimal candidates for this treatment. Phases III
trials are therefore justified.
2.3. Rhenium-188 Microspheres. Rhenium-188 (E훽max = 2.12
MeV; E𝛾 = 155 keV (15%); t1/2 = 16.9 h, max tissue penetration
= 11 mm), available through a 188W/188Re generator, offers
cost-effective convenient on-site availability, short half-life,
energetic 𝛽-particle, and emission of 𝛾-photons suitable for
imaging [83, 84]. It is thus a promising isotope for radionu-
clide therapy, especially treatment of liver malignancies.
Various particle materials have been considered for 188Re-
microspheres preparation [85], but, so far, only albumin
microspheres have been investigated in human.
2.3.1. Glass Microspheres. Chemically durable yttrium alu-
mino–silicate (YAS) microspheres, incorporating more than
50 wt% of rhenium oxide (ReO2), have been prepared and
neutron-irradiated in high-flux nuclear reactor [86]. These
microspheres were investigated in hepatoma bearing rats,
following intra-arterial injection, where they proved to be safe
and effective in diminishing tumour growth [87]. However,
low-cost and highly available natural rhenium consists of
two neutron activatable radioisotopes (185Re and 187Re, both
having large cross-sections for neutrons, yielding therapeutic
amounts within a few h), thus producing a mixture of 186Re
and 188Re, both 𝛽- and 𝛾-emitting radionuclides, with differ-
ent energies and different half-lives (cf. Table 1). The major
disadvantage is that dosimetric calculations are complicated
because of the two radioisotopes that must be considered.
The alternative would be to use enriched 187Re, but at a much
higher cost.
2.3.2. Resin Microspheres. There is only one example in the
literature of resin-based microspheres loaded with 188Re [88].
Aminex A-27 resin (Bio-Rad Inc, Hercules CA, USA) was
labelled by “adding [188Re]-perrhenate and SnCl2 to vacuum-
dried resin particles. Themixture was boiled and centrifuged
andmicrospheres were separated and resuspended in saline”.
They were tested in hepatoma-bearing rats by direct intra-
tumoural injection. “Survival over 60 days was significantly
better in the treated versus control group (80% versus 27%)”.
The same team compared this method with percutaneous
ethanol injection in VX2 rabbit model [89]. Mean survival
was 38.8 ± 6.2 days for the control group (rabbits treated with
saline injection), 55.8± 11.8 days for the percutaneous ethanol
injection group, and 68 ± 9.8 days for the rabbits treated with
188Re-microspheres. They thus concluded intra-tumoural
injection of 188Re-microspheres could be an alternative to
percutaneous ethanol injection and to intra-arterial injection.
2.3.3. Polymer Microspheres. Diverse natural and synthetic
polymers have been tested to prepare 188Re-microspheres
[85]. Poly(L-lactic acid) was mixed with jet-milled rhenium
powder and the microspheres were prepared with the solvent
evaporation similar to the method described above with
holmium. 22 𝜇m microspheres were neutron-activated for
3 h to give 188Re-PLA-microspheres [90]. Unfortunately,
these biodegradable microspheres were damaged by the high
neutron fluxes needed to achieve sufficiently high specific
activity required for the treatment of liver tumours. This
strategy was therefore abandoned. An alternative way to
load PLA microspheres is to encapsulate a 188Re-labelled
chelate inside the polymeric microspheres. Shukla et al. [91]
encapsulated 188Re-DMSA, with a low 20-30% yield, while
Yu et al. [92] derivatised PLA with a poly(histidine) tag
to attach the [188Re(CO)3(H2O)3]
+ complex directly onto
the polymer chains. They thus reported a radiolabelling
efficiency of 92%. Recently, encapsulation of 188Re-sulfur
colloids in PLA microspheres by an oil in-water (O/W)
emulsion solvent extraction procedurewas reported [93].The
13-48 𝜇m particles were labelled with over 99% efficiency
and were injected intravenously into mice, showing high
lung uptake. 188Re-colloids were also encapsulated in poly(L-
lactide-co-glycolide) (PLGA)microparticles, along with dox-
orubicin, and used for transarterial chemoradioembolization
in F344 rats [94]. 188Re/DOX@MS showed stronger tumour
inhibition than 188Re@MS and DOX@MS alone.
Biodegradable starch microspheres have been proposed
as an embolization agent to protect healthy liver tissue during
TAREwith 90Y-microspheres [95]. Verger et al. [96] proposed
to chemically modify starch so that it could chelate 188Re
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and developed a cold-kit labelling method to prepare 188Re-
starch-based microspheres with > 95% labelling yield. When
injected in DENA-induced rats, the activity was essentially
located in the tumorous parts of the liver. In the same way,
human serum albumin (HSA) labelled with technetium-99m
has been used for years for lung perfusion imaging, and
99mTc-labelled macroaggregates of albumin (MAA) are the
current method of choice to assess lung shunts and predict
90Y-microspheres dosimetry [97]. In 2000, Wunderlich et
al. proposed to label HSA with 188Re [98]. They found that
HSA B20 (ROTOP Pharmaka GmbH, Dresden, Germany)
gave uniform microparticles with a mean 25 𝜇m diameter
and were easily and stably labelled with generator-produced
188ReO4Na in the presence of tin chloride and HSA. They
also demonstrated high in vivo stability, with a preferential
lung uptake when injected intravenously in rats. A cold
kit method was subsequently developed [99]. The proposed
kit, consisting of three vials, enabled an almost quantitative
labelling yield and minimum handling. The preparation was
recently further optimised by Chen et al., using microwave
heating, thus shortening the reaction time from 1 h to 3 min
[100]. Tumour volume in the normal saline treated group
was 1803.2 mm3 at 54 days after tumour inoculation, while
tumour volumes in the 103.6 MBq and 240.5 MBq of 188Re-
HSA microspheres treated groups were 381 and 267.4 mm3
(P = 0.001 and 0.004), respectively, demonstrating the high
therapeutic efficacy of this modality.
188Re-HSA microspheres have been investigated in a
feasibility study in 10 patients with HCC (3) or colorectal liver
metastases (7) [101]. Patients were given0 13.6 ± 4.7 GBq of
188Re-microspheres selectively in the feeding artery of the
tumour. The urinary excretion rate was low (8.9 ± 3.8%IA
within 96 h). Response was assessed on CT: 2 patients had
PR, 5 patients had SD, and 3 patients had DP. The treatment
was well tolerated, with an acceptable rate of toxicity (30%
of grades I and II, and 10% of grade III toxicity), which was
reversible inmost patients within 14 days after treatment.This
treatment could thus represent a therapeutic option in these
patients, but it is not possible to draw any firm conclusions,
because of the small size and heterogeneity of the patient
group. A larger patient cohort is necessary. A second study
using 188Re-HSA microspheres was described by Nowicki
et al. [102]. This study included 13 patients with progressive
primary or secondary liver tumours. They received 3.8–12.4
GBq.The urinary excretion rate was low (6.5± 2.3%IAwithin
48 h). Mean overall survival was 7.1 months, and progression
free survival was 5.1 months. Treatment adverse events were
at an acceptable level, with 4 patients having grade 3 toxicity,
mostly due to cancer progression. This study confirms the
results of the first study and 188Re-HSAmicrospheres deserve
to be further investigated.
3. TARE with radiolabelled Lipiodol
The most used vector for intrahepatic administration is
Lipiodol. Lipiodol is an ethyl ester of iodinated fatty acids
derived from poppy seeds with a proportion of iodine of
approximately 38% by weight (i.e., 475 mg/mL). This iodised
oil was discovered in 1901 by Guerbet and is the first organic
iodinated contrast agent used for X-ray, in lymphography.
Nakakuma et al. have shown that Lipiodol is selectively
captured by hepatoma and by certain hepatic metastases,
of colonic, neuroendocrine and mammary origin [103].
Lipiodol has therefore been used for the detection of HCC,
then also for vectorising chemotherapeutic substances. Intra-
tumour retention time has also been shown to be significantly
greater than retention time in healthy liver, with retention
in tumour cells up to several months [104]. Replacement
of cold iodine with iodine-131, by an exchange reaction
on Lipiodol [105], makes it possible to obtain radiolabelled
Lipiodol, 131I-Lipiodol, which was successfully used for the
treatment of nonoperable HCC [106, 107]. Still, Iodine-131
possesses a high energy gamma emission and long half-
life (E훽max = 0.81 MeV; E𝛾 = 364 keV (81%); t1/2 = 8.02 d)
requiring hospitalisation in a radioprotected room for several
days, thus limiting its potential. Other therapeutic nuclides,
such as Yttrium-90 [108] and Rhenium-188 [109], have been
proposed to advantageously replace it. Radiolabelling and
clinical application of Lipiodol with Rhenium-188 have been
extensively reviewed elsewhere [110].
3.1. Lipiodol Radiolabelling. Initial trials to covalently label
Lipiodol with 188Re and 90Y revealed unsuccessful [111–113].
Solubilisation of a lipophilic radiocomplex into Lipiodol was
suggested as more suitable [114]. Several such 188Re-labelled
complexes [115–127] were subsequently proposed (Figures 3
and 4).
Lipiodol was also labelled with lipophilic chelates of
yttrium-90 and radiolanthanides, although literature is scarce
compared with rhenium-188. Oxine (8-hydroxyquinoline)
forms a lipid-soluble complex with trivalent metals and has
been used since the 1970s with indium-111 to label leukocytes
[128]. Based on this, it has been proposed to label Lipiodol
with yttrium-90 [129], holmium-166 [130], and lutetium-177
[131].Theprocedurewas however rather time-consuming and
the resulting complex lacked sufficient stability, leading to
undesirable bone uptake. Using the same analogy with 111In-
labelled leukocytes, 90Y-tropolonate has been investigated
to label Lipiodol [132]. The radiotracer showed increased
stability compared to oxinate and high tumour uptake,
but its stability was not satisfactory enough. Other com-
pounds mentioned in the literature include dithiocarba-
mate/phenanthroline 90Y-complex [133] and di(2-ethylhexyl)
orthophosphoric acid (P204), initially developed for solvent
extraction of metals [134], with no biological data. Ligands
used are summarised in Figure 3.
Since handling of high activities of beta-emitting ther-
apeutic radionuclides can lead to a high radiation burden
to the staff performing the preparations [135, 136], remote-
controlled procedures were developed [137–139]. This led to
a significant reduction of the received dose [140], in addition
to a more GMP-compliant preparation.
3.2. Clinical Outcome. 131I-labelled Lipiodol (Lipiocis) dates
back to the 1980s [141, 142]. Since then, many feasibility
studies and a few Phase III trials have been carried out,
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essentially for the management of inoperable HCCs [107,
110, 143]. Three small randomised controlled trials were
carried out for the palliative treatment of HCC with portal
vein thrombosis (PVT) and without PVT, and adjuvant
treatment after surgery, with respectively 129, 27, and 43
patients. Despite encouraging results, because of the subop-
timal properties of 131I and a more than expected lung tox-
icity [144], Lipiocis is not commercially available anymore
in Europe. In-house labelled 131I-Lipiodol is however still
under use in some countries, like for instance India [139].
To date, besides 131I-Lipiodol, only 188Re-labelled Lipiodol
has been assessed in human. No 90Y- or radiolanthanide-
labelled Lipiodol has been thus far investigated in clinics.
Four 188Re-chelates have been evaluated to prepare clinical
188Re-labelled Lipiodol [110], i.e., 188Re-TDD [115], 188Re-
HDD (now rebadged HTDD) [117], 188ReN-DEDC [125],
and 188Re-SSS [126] (Figure 4). Except one nonconclusive
case report with 188Re-TDD/Lipiodol [145], and two dose-
escalation studies with 188ReN-DEDC/Lipiodol [125] and
188Re-SSS/Lipiodol [146], which both demonstrated promis-
ing preliminary outcomes, most clinical studies were carried
out with 188Re-HDD/Lipiodol [147–158]. Despite high uri-
nary excretion [150] and difficulties to obtain high activities
because of low labelling yields [118], 188Re-HDD/Lipiodol
demonstrated favourable responses and appeared to be well
tolerated in dose escalation trials [148, 149], and in various
feasibility studies in more advanced forms of the disease [151,
152], as well as in second-line therapy after relapse following
a curative treatment [153, 154].
Following these encouraging results, an international
IAEA-sponsored multicentric Phase II trial was launched
[156–158]. 185 patients were included, receiving 1 to 4 treat-
ment doses, with activities ranging from 0.78 to 13.45 GBq.
The outcome of this study was 25% objective response (with
3% CR), 53% stabilised disease and 22% tumour progression,
with a median follow-up of 455 days. One- and two-year
survivals were, respectively, 46 and 23%. Tolerance was good.
In view of these results, a larger randomised Phase III study
appears to be required.
3.2.1. Other Therapeutic Applications. Lipiocis had received
marketing authorisation for the treatment of HCC with
PVT. 131I-Lipiodol was however also investigated in other
indications, such as in adjuvant and neoadjuvant settings,
where it, respectively, led to an increase in overall and disease-
free survivals [159] and to a decreased risk of recurrence
before transplantation or resection [160, 161]. To date, only
one preliminary study (with 5 patients) used 188Re-Lipiodol
to stabilise patients awaiting liver transplantation, demon-
strating its feasibility [162]. The advantage of 188Re-Lipiodol,
compared to 131I-Lipiodol, is the shorter half-life of 188Re,
making patients eligible for transplantation after 1 week,
while they had to wait for 4 weeks when treated with 131I-
Lipiodol. More patients are needed to be able to conclude on
its potential use in this indication.
Besides HCC, liver can be home to other primary and
secondary tumours, for which TACE with Lipiodol has
shown its efficiency and tolerability [163, 164]. Limited studies
using TARE with 131I-lipiodol have been published though.
Contradictory results have been obtained in pilot studies with
cholangiocarcinoma (CCA) [165, 166] and TARE is thus not
recommended [167], while treatment of hepatic metastases
could prove to be valuable [168, 169]. It would therefore be
interesting to assess the potential interest of 188Re-Lipiodol
in these indications, for which radiolabelled microspheres
(with either 90Y, 166Ho, or 188Re) have proven their safety and
efficacy.
4. Conclusions
Research on treatments for primary or secondary liver
tumours has been particularly active, at the preclinical and
clinical levels, following the successful introduction of 90Y-
microspheres in the therapeutic armamentarium. Among the
many methods to be investigated, 188Re-Lipiodol appears as
a relatively economical, safe, and attractive alternative to 90Y-
microspheres for the treatment of HCC. 166Ho-microspheres
also look particularly appealing, thanks to the multimodal
properties of holmium-166, and initial clinical findings,
especially for liver metastases. Large randomised Phase III
trials now need to take place, to confirm these encouraging
Phase I/II results. In order to be able to define the place of
TARE in treatment decision plans, comparisons with other
existing treatment modalities, notably targeted therapies and
newly developed immunotherapies, must be undertaken. It
is most probable that future treatment strategies may rely
on the combination with one or another of these therapies.
Ultimately, choice of the TARE modality will be made based
on local expertise and availability. Besides, many aspects
of TARE still remain a challenge, such as optimisation
of specific activity, determination of embolic distribution,
microdosimetry, and personalised dosimetry (pre- and post-
injection), as well as predictive response factors, requiring
further clinical and preclinical studies.
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